Extracorporeal membrane oxygenation (ECMO) reconsidered

Critical Care and Resuscitation

Volumn 12, Issue 2, 2010, Pages 131-135

  Moran, John L ^a,b   Chalwin, Richard P ^c   Graham, Petra L ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BAYES THEOREM; COST BENEFIT ANALYSIS; ECONOMICS; EXTRACORPOREAL OXYGENATION; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

BAYES THEOREM; COST-BENEFIT ANALYSIS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 77955059780     PISSN: 14412772     EISSN: 26529335     Source Type: Journal    
DOI: 10.1016/S1441-2772(23)01516-8     Document Type: Article

References (47)

1. Peek, G.J., Mugford, M., Tiruvoipati, R., et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374 (2009), 1351–1363.
2. The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators., Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA 302 (2009), 1888–1895.
3. Chalwin, R.P., Moran, J.L., Graham, P.L., The role of extracorporeal membrane oxygenation for treatment of the adult respiratory distress syndrome: a review and quantitative analysis. Anaesth Intensive Care 36 (2008), 152–161.
4. Putensen, C., Theuerkauf, N., Zinserling, J., et al. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med 151 (2009), 566–576.
5. Moran, J.L., Bersten, A.D., Solomon, P.J., Meta-analysis of controlled trials of ventilator therapy in acute lung injury and acute respiratory distress syndrome: an alternative perspective. Intensive Care Med 31 (2005), 227–235.
6. 2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 149 (1994), 295–305 [Erratum in Am J Respir Crit Care Med 1994; 149: 838.].
7. Zapol, W.M., Snider, M.T., Hill, J.D., et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 242 (1979), 2193–2196.
8. DerSimonian, R., Kacker, R., Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28 (2007), 105–114.
9. Spiegelhalter, D.J., Abrams, K.R., Myles, J.P., Bayesian approaches to clinical trials and health-care evaluation. 2004, John Wiley & Sons, Chichester.
10. Peek, G., Clemens, F., Elbourne, D., et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res, 6, 2006, 163.
11. Freemantle, N., Calvert, M., Wood, J., et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 289 (2003), 2554–2559.
12. Lauer, M.S., Topol, E.J., Clinical trials — multiple treatments, multiple end points, and multiple lessons. JAMA 289 (2003), 2575–2577.
13. Bersten, A.D., Edibam, C., Hunt, T., Moran, J., The Australian and New Zealand Intensive Care Society Clinical Trials Group. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian states. Am J Respir Crit Care Med 165 (2002), 443–448.
14. Krafft, P., Fridrich, P., Pernerstorfer, T., et al. The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations. Intensive Care Med 22 (1996), 519–529.
15. Luecke, T., Muench, E., Roth, H., et al. Predictors of mortality in ARDS patients referred to a tertiary care centre: a pilot study. Eur J Anaesthesiol 23 (2006), 403–410.
16. Kraemer, H.C., Mintz, J., Noda, A., et al. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 63 (2006), 484–489.
17. Phua, J.M., Badia, J.R., Ferguson, N.D., Acute respiratory distress syndrome and the Art of War. Crit Care Med 37 (2009), 1798–1799.
18. Annane, D., Improving clinical trials in the critically ill: unique challenge — sepsis. Crit Care Med 37:1 Suppl (2009), S117–S128.
19. Gould, A.L., Sample size re-estimation: recent developments and practical considerations. Stat Med 20 (2001), 2625–2643.
20. Browne, R.H., On the use of a pilot sample for sample size determination. Stat Med 14 (1995), 1933–1940.
21. Kieser, M., Wassmer, G., On the use of the upper confidence limit for the variance from a pilot sample for sample size determination. Biom J 38 (1996), 941–949.
22. Lachin, J.M., Statistical considerations in the intent-to-treat principle. Control Clin Trials 21 (2000), 167–189.
23. Sheiner, L.B., Rubin, D.B., Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 57 (1995), 6–15.
24. Stewart, W.H., Groundhog Day: cause and effect and the primary importance of the finite population induced by randomization. J Biopharm Stat 12 (2002), 93–105.
25. Stewart, W.H., Basing intention-to-treat on cause and effect criteria. Drug Inf J 38 (2004), 361–369.
26. Loeys, T., Goetghebeur, E., A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. Biometrics 59 (2003), 100–105.
27. Thalanany, M., Mugford, M., Hibbert, C., et al. Methods of data collection and analysis for the economic evaluation alongside a national, multi-centre trial in the UK: Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR). BMC Health Serv Res, 8, 2008, 94.
28. Lambert, P.C., Thompson, J.R., Weston, C.L., Dickman, P.W., Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8 (2007), 576–594.
29. Ghelani, D.R., Moran, J.L., Sloggett, A., et al. Long term survival of intensive care septic and hospital patient cohorts compared with the general Australian population: a relative survival approach. J Eval Clin Pract 15 (2009), 425–435.
30. O'Hagan, A., Stevens, J., The probability of cost-effectiveness. BMC Med Res Methodol, 2, 2002, 5.
31. Fenwick, E., O'Brien, B.J., Briggs, A., Cost-effectiveness acceptability curves — facts, fallacies and frequently asked questions. Health Econ 13 (2004), 405–415.
32. UK Collaborative ECMO Trial Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 348 (1996), 75–82.
33. Schwartz, D., Lellouch, J., Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20 (1967), 637–648.
34. Jennison, C., Turnbull, B.W., Group sequential methods with applications to clinical trials. 2000, Chapman and Hall/CRC, Boca Raton, Fla.
35. Mehta, C.R., Tsiatis, A.A., Flexible sample size considerations using information-based interim monitoring. Drug Inf J 35 (2001), 1095–1112.
36. The Acute Respiratory Distress Syndrome Network, (eds.) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 342, 2000, 1301–1308.
37. DeMets, D.L., Ware, J.H., Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 69 (1982), 661–663.
38. The ARDS Network, Prospective, randomized, multi-center trial of 12 mL/kg vs 6 mL/kg tidal volume positive pressure ventilation for treatment of acute lung injury and acute respiratory distress syndrome (ARMA). ARDSNet Study 01, Version III. 11 Sep 1998 http://www.ardsnet.org/system/files/armaprotocolV3_1998-09-11_0.pdf, 1998.
39. Montori, V.M., Devereaux, P.J., Neill, K.J., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294 (2005), 2203–2209.
40. Wheatley, K., Clayton, D., Be skeptical about large apparent treatment effects: the case of an MRC AML12 randomization. Control Clin Trials 24 (2003), 66–70.
41. White, D.B., Angus, D.C., Preparing for the sickest patients with 2009 influenza A(H1N1). JAMA 302 (2009), 1905–1906.
42. Adhikari, N.K., Burns, K.E., Friedrich, J.O., et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ, 334, 2007, 779.
43. Taccone, P., Pesenti, A., Latini, R., et al. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 302 (2009), 1977–1984.
44. Kraemer, H.C., Frank, E., Kupfer, D.J., Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 296 (2006), 1286–1289.
45. Senn, S., Harrell, F., On wisdom after the event. J Clin Epidemiol 50 (1997), 749–751.
46. Neuzil, K.M., Pandemic influenza vaccine policy — considering the early evidence. N Engl J Med, 361, 2009, e59.
47. Emerson, S.S., Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Biometrics 51 (1995), 1152–1162.